These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26022650)

  • 1. Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.
    Kojima M; Ogiya D; Kawai H; Miyamoto M; Ohmachi K; Ogawa Y; Nakamura N; Ando K
    Acta Haematol; 2015; 134(3):181-2. PubMed ID: 26022650
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
    Canellos GP; Duggan D; Johnson J; Niedzwiecki D
    J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
    [No Abstract]   [Full Text] [Related]  

  • 4. [Our experience with the treatment of Hodgkin lymphoma patients].
    Illés Á; Garai I; Miltényi Z
    Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
    Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
    Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
    Lopez M
    Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
    [No Abstract]   [Full Text] [Related]  

  • 9. Classical Hodgkin's lymphoma: past, present and future perspectives.
    Eyre TA; King AJ; Collins GP
    Br J Hosp Med (Lond); 2013 Nov; 74(11):612-8. PubMed ID: 24220522
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequencing therapies in Hodgkin lymphoma.
    Phillips EH; Collins GP; Cwynarski K
    Lancet Haematol; 2021 Aug; 8(8):e537-e539. PubMed ID: 34329571
    [No Abstract]   [Full Text] [Related]  

  • 11. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
    Diehl V
    J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.
    Narkhede M; Sarraf Yazdy M; Cheson B
    Expert Rev Hematol; 2018 Oct; 11(10):773-780. PubMed ID: 30139285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marathon running during chemotherapy: where are the limits?
    Dimeo FC
    Onkologie; 2011; 34(5):230. PubMed ID: 21577027
    [No Abstract]   [Full Text] [Related]  

  • 16. Marathon run under chemotherapy: is it possible?
    Bernhörster M; Rosenhagen A; Vogt L; Thiel C; Jäger E; Banzer W
    Onkologie; 2011; 34(5):259-61. PubMed ID: 21577032
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematuria--a rare presentation of Hodgkin lymphoma.
    Dembla V; Walker BN; Elkins SL; Files JC
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):788-90; discussion 791-2. PubMed ID: 22252582
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option.
    Canellos GP
    J Clin Oncol; 2005 Jul; 23(21):4574-6. PubMed ID: 15837972
    [No Abstract]   [Full Text] [Related]  

  • 20. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
    Cao H; Yamamoto K; Yang LX; Weber R
    Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.